CanSino Biologics Inc Asset Resilience Ratio
CanSino Biologics Inc asset resilience ratio. CanSino Biologics Inc (CJH) has an Asset Resilience Ratio of 19.62% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See CanSino Biologics Inc (CJH) defensive interval to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of CanSino Biologics Inc (2016–2025)
Asset resilience ratio of CanSino Biologics Inc from 2016 to 2025. This chart shows how CanSino Biologics Inc's Asset Resilience Ratio has changed over time. Read CJH total debt and obligations for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down CanSino Biologics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see CanSino Biologics Inc assets under control.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €1.41 Billion | 19.62% |
| Total Liquid Assets | €1.41 Billion | 19.62% |
Asset Resilience Insights
- Good Liquidity Position: CanSino Biologics Inc maintains a healthy 19.62% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
CanSino Biologics Inc Industry Peers by Asset Resilience Ratio
Compare CanSino Biologics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Viatris Inc
NASDAQ:VTRS |
Drug Manufacturers - Specialty & Generic | 1.48% |
|
Tianjin Zhongxin Pharmaceutical Group Corp Ltd
SHG:600329 |
Drug Manufacturers - Specialty & Generic | 5.92% |
|
Walvax BioTech
SHE:300142 |
Drug Manufacturers - Specialty & Generic | 2.20% |
|
Curaleaf Holdings Inc.
TO:CURA |
Drug Manufacturers - Specialty & Generic | 3.73% |
|
Tianjin Chase Sun Pharmaceutical Co Ltd
SHE:300026 |
Drug Manufacturers - Specialty & Generic | -0.89% |
|
Changzhou Qianhong Biopharma Co Ltd
SHE:002550 |
Drug Manufacturers - Specialty & Generic | 18.70% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
|
Harbin Gloria Pharmaceuticals
SHE:002437 |
Drug Manufacturers - Specialty & Generic | 9.04% |
CanSino Biologics Inc Asset Resilience Ratio by Year (2016–2025)
CanSino Biologics Inc asset resilience ratio by year from 2016 to 2025. The table below shows the annual Asset Resilience Ratio data for CanSino Biologics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 19.62% | €1.41 Billion ≈ $1.65 Billion |
€7.18 Billion ≈ $8.39 Billion |
-0.97pp |
| 2024-12-31 | 20.60% | €1.64 Billion ≈ $1.92 Billion |
€7.96 Billion ≈ $9.30 Billion |
-1.65pp |
| 2023-12-31 | 22.25% | €2.07 Billion ≈ $2.42 Billion |
€9.32 Billion ≈ $10.89 Billion |
-0.01pp |
| 2022-12-31 | 22.25% | €2.55 Billion ≈ $2.98 Billion |
€11.47 Billion ≈ $13.41 Billion |
+2.66pp |
| 2021-12-31 | 19.59% | €2.33 Billion ≈ $2.72 Billion |
€11.87 Billion ≈ $13.88 Billion |
+9.71pp |
| 2020-12-31 | 9.88% | €666.64 Million ≈ $779.37 Million |
€6.75 Billion ≈ $7.89 Billion |
-21.07pp |
| 2019-12-31 | 30.95% | €552.34 Million ≈ $645.75 Million |
€1.78 Billion ≈ $2.09 Billion |
+13.36pp |
| 2018-12-31 | 17.59% | €140.00 Million ≈ $163.67 Million |
€795.88 Million ≈ $930.46 Million |
-28.88pp |
| 2017-12-31 | 46.47% | €402.64 Million ≈ $470.72 Million |
€866.36 Million ≈ $1.01 Billion |
+17.66pp |
| 2016-12-31 | 28.82% | €94.00 Million ≈ $109.90 Million |
€326.17 Million ≈ $381.33 Million |
-- |
About CanSino Biologics Inc
CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People's Republic of China. The company develops Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides. It develops DTcP vaccine for infants and DTcP Booster vaccine, which are in Phase I clinical … Read more